

MARKET ACCESS

Value-Based Contracting Evolution

Value-Based Contracting Evolution provides insights into value-based contracting engagements between biopharmaceutical companies and payers and integrated delivery networks (IDNs).

- How prevalent are value-based contracts (VBCs) between payers and biopharmaceutical companies today?
- What therapeutic categories are currently impacted by VBCs and which will be future targets?
- What is driving interest in and growth of VBCs?
- Which biopharmaceutical companies are leading the VBC charge?
- What is the prevalence of value-based agreements between IDNs and biopharmaceutical companies?
- What types of biopharma-IDN value-based agreements are growing in participation?
- How do value-based agreements impact product access?

Use **Value-Based Contracting Evolution** to:

- Identify best practices in value-based contracting between biopharmaceutical companies and payers as well as IDNs
- Assess most common and successful types of VBCs, including key components and goals
- Evaluate impact of value-based contracting on prescribing and formulary decisions

Company-Payer Value-Based Contracting Trends TBD	<ul style="list-style-type: none"> • Prevalence of and level of payer success in VBCs • Therapeutic areas most often gaining inclusion in VBCs • Barriers to successful participation in VBCs
Company-IDN Value-Based Relationship Trends TBD	<ul style="list-style-type: none"> • Prevalence and type of value-based agreements between IDNs and companies • Impact of value-based agreements on product access

This product may also include relevant market alerts, real-time assessments of recent changes, or discussions of market events. EVERSANA reserves the right to change the timing and/or topics of its syndicated research publications.